Leveraging Molecular Diagnostic Technologies to Close the Global Cancer Pathology Gap
JCO Glob Oncol
.
2022 Oct:8:e2200182.
doi: 10.1200/GO.22.00182.
Authors
Parsa Erfani
1
,
Michael Bates
2
,
Pat Garcia-Gonzalez
3
,
Dan A Milner
4
5
,
Timothy R Rebbeck
5
,
Deogratias Ruhangaza
6
,
Lawrence N Shulman
7
,
Temidayo Fadelu
1
8
Affiliations
1
Harvard Medical School, Boston, MA.
2
Medical and Scientific Affairs, Oncology, Cepheid, Sunnyvale, CA.
3
The Max Foundation, Global Headquarters, Seattle, WA.
4
American Society for Clinical Pathology, Chicago, IL.
5
Harvard TH Chan School of Public Health, Boston, MA.
6
Department of Pathology, Butaro Cancer Center of Excellence, Burera, Rwanda.
7
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
8
Dana-Farber Cancer Institute, Boston, MA.
PMID:
36252158
PMCID:
PMC9812500
DOI:
10.1200/GO.22.00182
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
MeSH terms
Humans
Neoplasms* / diagnosis
Neoplasms* / therapy
Pathology, Molecular*
Technology
Grants and funding
D43 TW010543/TW/FIC NIH HHS/United States